Left arrow Go Back

STQARRIJA MILL-AWTORITÀ TAL-MEDIĊINI TA’ MALTA

PR1897
Date Icon 09/12/2004

The Committee for Human Medicinal Products (CHMP), the Scientific Committee of the European Medicines Agency (EMEA) at an extraordinary meeting held on the 8 December 2004 has confirmed its previous decision of last April, that the use of Paroxetine in adults continues to show a favourable risk/benefit ratio.  

Moreover the committee reiterated its previous decision, that there should be a warning concerning the risk of abnormal behaviour in children and adolescents on the above-mentioned medication.  

The committee stated that this warning also applies to children prescribed Serotonin Selective Re-uptake inhibitors (SSRIs) and Serotonin – Norepinephrine Re-uptake Inhibitors (SNRIs), about which there is information that they may have adverse effects.  

The committee further wishes to inform prescribers, patients and carers that:  

SSRI and SNRI preparations are not authorised for use in children and adolescents suffering from depression or excessive anxiety.

Clinical trials have shown that this type of medication is associated with increased risks in children and adolescents.

The doctor, however, may use these medicines in children and adolescents in certain cases based on clinical need provided that there is close medical supervision.

Patients should never discontinue the use of these medicines abruptly but should phase them out gradually over weeks or months under medical supervision

If there are any queries or doubts regarding the use of these medications, one should consult his treating doctor to discuss treatment.

The above concerns the following products that might be on the local market:  

Atomoxetine, Citalopram (Cipram®, Oropram®), Duloxetin, Escitalopram (Cipralex®), Fluoxetine (Anxetin®, APO-Fluoxetine®, Eurozithro®, Flonital®, Flunil®, Fluocim®, Fluoxetine Delta®, Fluxil®, Magrilan®, Novo-Fluoxetine®, Oxacitin®, Prozac®, Prozac® Weekly, Salipax®, Surafem®, Zactin®), Fluvoxamine (Faverin®, Fluvoxamine®, NOVO-Fluvoxamine®), Mianserin (Lantanon®, Mianserin®), Milnacipran (IXEL®), Mirtazapine, Paroxetine (Paxetin®, Seroxat®) Reboxetine (Edronax®), Sertraline (Lustral®), Venlafaxine (Efexor®, Efexor® Modified Release XL)

Share this Press Release Icon socials Icon socials Icon socials Icon socials

Other Press Releases:

STQARRIJA MILL-UFFIĊĊJU TAD-DEPUTAT PRIM MINISTRU U MINISTERU GĦAS-SAĦĦA  Ċertifikazzjoni internazzjonali tal-ogħla livell għad-dipartiment tar-radjoterapija fiċ-Ċentru tal-Onkoloġija Sir Anthony Mamo

PR261947

STQARRIJA MILL-UFFIĊĊJU TAD-DEPUTAT PRIM MINISTRU U MINISTERU GĦAS-SAĦĦA Ċ...

STQARRIJA MILL-MINISTERU GĦALL-EDUKAZZJONI U L-ISPORT  Aktar minn 1,800 student jiggradwaw mill-Università ta’ Malta

PR261946

STQARRIJA MILL-MINISTERU GĦALL-EDUKAZZJONI U L-ISPORT Aktar minn 1,800 stu...

More Press Releases Right arrow